{
  "url": "https://www.benzinga.com/pressreleases/25/08/g47300322/hutchmed-announces-appointment-of-acting-chief-executive-officer",
  "authorsByline": "Globe Newswire",
  "articleId": "9246577cbb4a4dfa9b866c8585367a12",
  "source": {
    "domain": "benzinga.com",
    "paywall": false,
    "location": {
      "country": "us",
      "state": "MI",
      "county": "Wayne County",
      "city": "Detroit",
      "coordinates": {
        "lat": 42.3315509,
        "lon": -83.0466403
      }
    }
  },
  "imageUrl": "http://benzinga.com/next-assets/images/schema-image-default.png",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-24T20:20:00-04:00",
  "addDate": "2025-08-25T00:34:04.109209+00:00",
  "refreshDate": "2025-08-25T00:34:04.109211+00:00",
  "score": 1.0,
  "title": "HUTCHMED Announces Appointment of Acting Chief Executive Officer - HUTCHMED (China) (NASDAQ:HCM)",
  "description": "HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (\"HUTCHMED\") (Nasdaq/AIM:\u200bHCM; HKEX:\u200b13) today announces that Dr Weiguo Su, an Executive Director of the Company,",
  "content": "HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (\"HUTCHMED\") (Nasdaq/AIM:\u200bHCM; HKEX:\u200b13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer.\n\nDr Dan Eldar, Chairman and Non-executive Director, said, \"The Board expresses its full support for Dr Su and wishes him a speedy recovery. We thank Mr Cheng for his agreement to assume responsibility for overseeing the day-to-day operations and management of the Company during this interim period. The board has full confidence in Mr. Cheng's capabilities to lead the Company. The Board is confident that all research, development and commercial initiatives will remain on track.\"\n\nDr Weiguo Su, Executive Director, said, \"This has been a very difficult decision to make, but at this time my focus must be on my health. I am certain that the Board, Mr Cheng and everyone at HUTCHMED will ensure the continued execution of our strategy and that the scientific team will continue its work on the determined drug research and discovery pipeline as planned. I would like to thank everyone for their support and look forward to being able to return to work as soon as possible.\"\n\nMr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer, said, \"Over the last 20 years under Dr Su's leadership and the contribution of the entire team, HUTCHMED has built a portfolio of drugs and a strategy to successfully build new platforms and capabilities to deliver additional value. Together with our management team we shall endeavor to ensure on-track delivery. My best wishes to Dr Su for a speedy recovery.\"\n\nHUTCHMED (Nasdaq/AIM:\u200bHCM; HKEX:\u200b13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.\n\nThis announcement contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to HUTCHMED's board of directors are not e\ufb00ective in their respective positions, the di\ufb00iculty in locating and recruiting suitable candidates for its board of directors and the management di\ufb00iculties which may arise from changes in HUTCHMED's board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on A\u0406M and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.\n\nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).\n\nDisclosure pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited\n\nMr Cheng, aged 58, has been an Executive Director since 2011 and Chief Financial Officer of the Company since 2008. He is a member of the Sustainability Committee of the Company. Prior to joining the Company, Mr Cheng was vice president, finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008. Mr Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia and then KPMG in Beijing before spending eight years with Nestl\u00e9 China where he was in charge of a number of finance and control functions in various operations. Mr Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is an associate of Chartered Accountants Australia and New Zealand. Mr Cheng does not have any relationship with any other Directors, senior management, substantial or controlling shareholders of the Company. As at the date of this announcement, Mr Cheng had a personal interest in 2,936,430 ordinary shares of the Company (\"Shares\"), representing approximately 0.34% of the issued Shares, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The term of Mr Cheng's service as an Executive Director of the Company is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the provisions of the Articles of Association. The director's fees of Mr Cheng as an Executive Director and a member of the Sustainability Committee of the Company under his appointment letter are US$70,000 and US$5,000 per annum respectively. The emoluments specified in the service agreement appointing Mr Cheng as Chief Financial Officer of the Company are US$490,513 per annum in salary and discretionary bonus which the Company may decide to pay. There will also be equity compensation of up to US$779,934 per annum. Such emoluments are determined by reference to the performance and profitability of the Company as well as his personal performance, remuneration benchmark in the industry and the prevailing market conditions. Such fees are subject to review from time to time and proration for an incomplete year of service. Save as disclosed above, there are no other matters concerning Mr Cheng that are required to be brought to the attention of the shareholders, nor is there other information that is required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.",
  "medium": "Article",
  "links": [
    "https://www.globenewswire.com/Tracker?data=H_EPXcqf4ioMeHa92XmStkFwjlKPQkvNVrqIMwbWdi5Dq34_ylzFViTiT4Q2iQdw_QyWWKHI-p7D8mztXgUf2Q==",
    "https://www.globenewswire.com/Tracker?data=xnVcumhVTkxf8fzXKb1x5zXXjnD-WKohgFIGJm-5z0UIeDP5b7PvduPJCA-JNm4KdCTIdjPwxoatgS-rxHe9fmr-Xq-Vg8WuxFiW4oyoMzE=",
    "https://www.globenewswire.com/Tracker?data=N7vtuOgpSmkMupBCk_HiPtyjpth1l_ngFAeVRZgBoxQgU9bFnVBPH-76Vam5gi5JJHq-xiIj7h-Jbx3MIfUiFZXT4MVu6UG9mVGY7Mz_qvk=",
    "https://www.globenewswire.com/NewsRoom/AttachmentNg/085957ad-3bec-49ee-b13e-39961b83c7be"
  ],
  "labels": [
    {
      "name": "Press Release"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Mr Cheng",
      "weight": 0.08759637
    },
    {
      "name": "Mr Johnny Cheng",
      "weight": 0.08344457
    },
    {
      "name": "Chief Executive Officer",
      "weight": 0.07471191
    },
    {
      "name": "Executive Director",
      "weight": 0.07228242
    },
    {
      "name": "Acting Chief Executive Officer",
      "weight": 0.07215843
    },
    {
      "name": "Johnny Cheng",
      "weight": 0.07022983
    },
    {
      "name": "Cheng",
      "weight": 0.06997876
    },
    {
      "name": "Company",
      "weight": 0.068262376
    },
    {
      "name": "Chief Financial Officer",
      "weight": 0.06417071
    },
    {
      "name": "HUTCHMED",
      "weight": 0.061473045
    }
  ],
  "topics": [
    {
      "name": "Markets"
    },
    {
      "name": "Stocks"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.98828125
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.72216796875
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.6494140625
    }
  ],
  "sentiment": {
    "positive": 0.620507,
    "negative": 0.045081254,
    "neutral": 0.33441168
  },
  "summary": "HUTCHMED (China) Limited (Nasdaq/AIM:\u200bHCM; HKEX:13) has announced that Dr Weiguo Su will take a leave of absence from his duties as Chief Executive Officer due to health reasons. The Board of Directors has appointed Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officers. The board has full confidence in Cheng's ability to lead the company and its research, development and commercial initiatives remain on track. This announcement includes forward-looking statements that reflect HUTCHED's current expectations regarding future events. These statements are subject to numerous risks and uncertainties, including a lack of current or future appointees in their positions, a difficulty in finding suitable candidates for HutCHMED's board of directors, and potential changes to HUTChMED's governance.",
  "shortSummary": "HUTCHMED (China) appointed Johnny Cheng as Acting Chief Executive Officer, temporarily replacing Dr Weiguo Su due to health reasons, with immediate effect.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "3417a96b9ef940eabe0e5b230f0b0c3c",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.globenewswire.com/Tracker?data=xnVcumhVTkxf8fzXKb1x5zXXjnD-WKohgFIGJm-5z0UIeDP5b7PvduPJCA-JNm4KdCTIdjPwxoatgS-rxHe9fmr-Xq-Vg8WuxFiW4oyoMzE=",
      "text": "Primary results from the interim analysis of the SACHI Phase III study were presented in a late-breaking oral presentation during the American Society of Clinical Oncology Annual Meeting #ASCO25. The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study. https://lnkd.in/gUKMatwc \ud83d\udd14 HUTCHMED will host a webcast to discuss the data presented at the ASCO Annual Meeting at 8:30 -9:00 am HKT on Tuesday, June 3, 2025 (8:30 \u2013 9:00 pm EDT on June 2, 2025).\nAbout us\nHUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us here on LinkedIn.\n- Website\n-\nhttps://www.hutch-med.com\nExternal link for HUTCHMED\n- Industry\n- Biotechnology Research\n- Company size\n- 5,001-10,000 employees\n- Headquarters\n- Hong Kong\n- Type\n- Public Company\n- Specialties\n- Pharmaceutical, Biopharmaceutical, Innovation, Research and Development, Oncology, Hematology, Immunology, Inflammation, Cancer, and Targeted Therapy\nLocations\n-\nPrimary\nGet directions\nMetropolis Tower, 10 Metropolis Drive, Hung Hom\nLevel 18\nHong Kong, HK\n-\nGet directions\n917 Halei Road, Building 4, Zhangjiang Hi-Tech Park\nPudong, Shanghai 201203, CN\n-\nGet directions\n25A Vreeland Road\nSuite 304\nFlorham Park, NJ 07932, US\nEmployees at HUTCHMED\nUpdates\n-\nWe are pleased to announce the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS\u00ae (savolitinib) and TAGRISSO\u00ae (osimertinib) as a first-line treatment in certain non-small cell lung cancer patients whose tumors harbor EGFR mutation and MET overexpression. https://lnkd.in/gUehiEkF\n-\nWe are delighted to report our 2025 Half Year Results and provide updates on key clinical and commercial developments. https://lnkd.in/gyb7ENsx With a strong balance sheet, robust operations and an exciting new ATTC platform, HUTCHMED is ready to enter a new phase of growth. Our 20 years of knowledge of in-house discovery, experience in running large-scale pivotal trials, collaboration with international partners and success in obtaining global regulatory approvals empower us to bring forth more innovative medicines to address large unmet needs around the world.\n-\nWe will be announcing our 2025 interim results on Thursday, August 7, 2025. Management team of HUTCHMED will host a presentation for analysts and investors to discuss the interim financial results, followed by a Q&A session.\nThis content isn\u2019t available here\nAccess this content and more in the LinkedIn app\n-\nHUTCHMED reposted this\nHonored to join Peter Yan and Eric Ng at the SCMP China Conference 2025 earlier this week to talk about the biotech revolution in China, where we explored the development of the pharmaceutical industry in Hong Kong and the mainland, and the trends and recent challenges shaping the sector today. Thank you to South China Morning Post SCMP for hosting such a timely conversation. #CCHK2025 #SCMPLive #ChinaConference\n-\nWe are pleased to announce that the combination of ORPATHYS\u00ae (savolitinib) and TAGRISSO\u00ae (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR TKI therapy. https://lnkd.in/gws4r6Cz\n-\nWe are pleased to share that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor has been accepted for review by the China National Medical Products Administration (NMPA). https://lnkd.in/gMhyW92B\n-\nNew data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology #ASCO25 Annual Meeting taking place on May 30 \u2013 June 3, 2025 in Chicago, USA. https://lnkd.in/gCcS6cer\n-\nS&P Global, a leading global rating agency, recently published the S&P Global Sustainability Yearbook China 2025. HUTCHMED was recognized for its outstanding performance, ranking in the top 10% of the 2024 Corporate Sustainability Assessment (CSA) and securing its first-ever inclusion in the Yearbook. https://lnkd.in/e59Evk2C The 2024 S&P Global CSA used 62 industry-specific questionnaires. In each industry, only the top 15% of S&P Global CSA-rated companies or the highest-rated companies within the industry are qualified for consideration for inclusion in the Yearbook. As of March 2025, a total of 1,662 companies have obtained this qualification, and only 164 companies were finally selected. The inclusion in the Yearbook is an honored accolade for HUTCHMED."
    }
  ],
  "argos_summary": "HUTCHMED announced that CEO Dr Weiguo Su will take a health\u2011related leave and CFO Johnny Cheng will serve as Acting CEO, with the board confident that research, development and commercial initiatives will remain on track under his interim leadership. The company highlighted recent clinical milestones, including the SACHI Phase III study showing a progression\u2011free survival benefit for savolitinib plus osimertinib, completion of enrollment in the SANOVO study, and upcoming ASCO presentations and interim financial results. HUTCHMED also received recognition in the S&P Global Sustainability Yearbook China 2025 for its corporate sustainability performance.",
  "argos_id": "RAV2UWRTT"
}